

Safe Harbor Statement

Statements in this presentation and our commentary and responses to questions that are not strictly historical may be "forward-looking" statements, which involve risks and uncertainties, and Emerson undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include the scope, duration and ultimate impacts of the Russia-Ukraine and other global conflicts, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, cybersecurity, tariffs, competitive and technological factors, inflation, among others, as set forth in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. The outlook contained herein represents the Company's expectation for its consolidated results, other than as noted herein.

Non-GAAP Measures

In this presentation we will discuss some non-GAAP measures in talking about our company's performance, and the reconciliation of those measures to the most comparable GAAP measures is contained within this presentation or available at our website, <u>www.Emerson.com</u>, under Investors.

Continuing Operations

All financial metrics in this presentation are on a continuing operations basis, unless otherwise noted. Please refer to endnotes for the definition of certain terms used in this presentation.

Key Messages



Current End-Market Demand

3% underlying orders growth in Q3 – process and hybrid up MSD and discrete down LSD

Expecting LSD growth in H2 and for the full year



Solid Q3 Performance

Operating leverage, adjusted EPS and free cash flow all exceeded Q3 expectations with orders and sales in line with guidance



Test & Measurement Update

Q3 pace of orders activity slightly below expectations while profitability in line due to impact of synergy realization

Now expecting fiscal 2024 sales to be \$1.45 - \$1.5B and adjusted EPS of \$0.42 - \$0.44



Updating Full Year Guidance

Adjusting guidance for underlying sales to mid-point of prior guide and increasing guidance for adjusted EPS at the mid-point and free cash flow

Considers current state of discrete end markets, softer China and strong Q3 from AspenTech


2024 Q3 Key Metrics

	Results	Prior Guidance
Underlying Orders Growth ¹	3%	
Underlying Sales Growth	3%	3% – 4.5%
Gross Profit Margin	52.8%	
Operating Leverage ²	67%	Mid 30s
Adjusted EPS	\$1.43	\$1.38 – \$1.42
Free Cash Flow	\$975M	

¹ Excludes AspenTech 2 Excludes Test & Measurement

Sustained Strength in Large Projects

PROJECT FUNNEL



PROJECT WINS



GROWTH PLATFORM WINS

Lithium Mining → Nemaska Lithium

Renewables → Large Indian **Renewable Energy Company**

Green Hydrogen → **ACWA Power**

Breakthrough Innovation

Softwaredefined automation

Updated Ovation Automation Platform to include softwaredefined architecture to help customers better leverage data, new technologies and artificial intelligence (AI)



Portfolio Management

Simplification


Announced definitive agreement to sell remaining interests in Copeland

Closed Copeland note receivable August 2


Expect to close equity stake by the end of August

2024 Q3 Performance Summary

Sales



Adjusted Segment EBITA




Price-cost and cost reductions drove margin expansion

Operating leverage²: 67%

Test & Measurement 21.4% Adjusted EBITA

Adjusted EPS




Solid operational performance

Test & Measurement contributed \$0.09

AspenTech increased \$0.03 versus prior year

Free Cash Flow




Above expectations driven by working capital improvements

Free cash flow margin of 22.3%

YTD of \$2.0B up 31% versus prior year

1 Excludes AspenTech 2 Excludes Test & Measurement

Q3 Adjusted EPS Bridge



2024 Continuing Operations Guidance

	2024
Net Sales Growth	~15%
FX Acquisitions (NI) Divestitures	~(0.5 pts) ~9.5 pts ~0 pts
Underlying Sales Growth	~6%
Operating Leverage ¹	Mid to High 40s
Adjusted EPS	\$5.45 – \$5.50
Test & Measurement Contribution ²	\$0.42 - \$0.44
AspenTech Contribution	\$0.32 – \$0.34
Free Cash Flow	~\$2.8B

Share repurchase: ~\$300M

Dividend payments: \$1.2B

Tax rate: ~22%

Appendix

Corporate and Other Items

(in millions)	2024 Q3	2024 Expectations
Stock Compensation – GAAP	(\$56)	~(\$260)
Integration-Related Stock Compensation Expense	\$9	~\$55
Adjusted Stock Compensation – Non-GAAP	(\$47)	~(\$205)
Pension	\$38	~\$145
Corporate & Other – GAAP	(\$38)	~(\$605)
Restructuring and Related Costs	\$1	~\$5
Acquisition / Divestiture Fees and Related Costs	\$13	~\$170
Amortization of Acquisition-Related Inventory Step-Up		\$231
Loss on Divestiture of Business		\$39
Adjusted Corporate & Other – Non-GAAP	(\$24)	~(\$160)
Interest Income / (Expense)¹	(\$32)	~(\$90)
Non-Controlling Interest – GAAP	(\$23)	~\$20
Amortization of Intangibles (AspenTech)	(\$40)	~(\$160)
Adjusted Non-Controlling Interest – Non-GAAP	(\$63)	~(\$140)
Average Diluted Share Count	574.8	~574

Sale of Remaining Copeland Interest and Note Receivable Agreements Entered June 6, 2024

SUMMARY OF TRANSACTIONS

\$3.5B Transaction Value including pretax cash proceeds and net release of future indemnity obligations

~\$2.9B After-Tax Proceeds which is intended to be used to pay off existing debt obligations

~\$0.2B expected net pretax gain of both transactions together

INDIVIDUAL TRANSACTIONS

Sale of 40% Copeland Equity Interest

to Blackstone & co-investors

Expected close in August 2024

Sale of Copeland Note Receivable

to Copeland

Closed August 2, 2024

\$279M Book Value loss (excl. from Adj. EPS)

FINANCIAL STATEMENT PRESENTATION SUMMA	ΔF	V	ľ			8	1	Ì	١	١	١	١	١	١	١	١	1	1	1	2	?	3	ł	,		ł	?	₹	₹	1	Ì	١	١	١	Ì	١	1	1	Ì	1	₹	3						2	2	5		i	i	i	i	ľ	ı	ı	ı	ľ	ľ	ľ	ľ	ľ	i	i	i	i	i	i	i			i	i	i	i	ı	i	i	i	i	i	i	i	i	i	i	i										ľ	ı	ı	ı	l	١	Į	ī	A	ļ	ı	ı	I	l	١	ı	ı	1	١	١		J		ı	1	3	;	ŀ		l	J	N	h				Į.	ľ	ı
Δ1			i		ì	ì	2	₹	₹	₹	₹	₹	₹	₹	₹	₹	3	2	2		2		ì	ì	ì	ì	2	2	2	3	₹	₹	₹	₹	₹	₹	₹	3	₹	2	2	ì	ì	ì		ì	ì			i	i			i	i	i									i	i	i	i	i		i					i	i	i	i	i	i	i	i	i	i	i	i	i	i		i	i	i	i	i	i	i		i				ı	l	l	V	N	4	AΙ	A	A	IAI	ИΑІ	MAI	MAI	IMAI	ИΜА	MMAI	MMAI	IMMAI	JMMAI	JMMAI	UMMAI	UMMA	SUMMAI	SUMMAI	SUMMA	SUMMA	SUMMA	SUMMA	N SUMMAI	N SUMMA	N SUMMAI	DN SUMMAI	ON SUMMAI	ON SUMMAI	ON SUMMAI
Δ1	i		i	i		ì	2	₹	₹	₹	₹	₹	₹	₹	₹	₹	₹	2	2		1		ì	ì	ì	ì	1	2	2	2	₹	₹	₹	₹	₹	₹	₹	2	₹	2	2	ì	ì	ì	ì	ì	ì	ì		ľ	i	i	i	i	i	i								Ì	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	i	ľ	ľ	i	i	ľ	ľ	ľ	i	i					l	l	V	N	4	AΙ	A	A	IAI	ИΑІ	MAI	MAI	IMAI	ИΜА	MMAI	MMAI	IMMAI	JMMAI	JMMAI	UMMAI	UMMA	SUMMAI	SUMMAI	SUMMA	SUMMA	SUMMA	SUMMA	N SUMMAI	N SUMMA	N SUMMAI	DN SUMMAI	ON SUMMAI	ON SUMMAI	ON SUMMAI
41	i		i	i			2	₹	₹	₹	₹	₹	₹	₹	₹	₹	2	2	2		2				i		2	2	2	2	₹	₹	₹	₹	₹	₹	3	2	₹	2	2			ì	i	i	ì	i	i		i		i	i	i	i	ı	ĺ		ľ	ľ	ľ	ľ	ľ	i	i	i	i	i		i			i	i	i	i	i	i	i	i	i	i	i	i	i	i	i					1	1					i	ĺ		ĺ		ı	l	۱	١	4	А	A	Α	IA	ИΑ	MA	MA	IMA	ИΜА	MMA	MMA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	l	l	l		i		R	R	R	R	R	R	R	R	R	R	R	R	R	5	3	-		ī	ī		3	R	R	R	R	R	R	R	R	R	R	R	R	R	R		ī		i	ī		i	i	Ì						ı	ı	ı	l	ı	ı	ı	ı	ı																											Ì	Ì	i	i	Ì	Ì	Ì			ı	ı	ı	Į	ı	ļ	١	١	4	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	IVIVIA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	l	l	l		i		R	R	R	R	R	R	R	R	R	R	R	R	8	-	3	F		ī	ī		3	R	R	R	R	R	R	R	R	R	R	R	R	R	8		ī		i	ī		i	i	Ì						ı	ı	ı	ı	ı	ı	ı	ı	ı																											Ì	Ì	i	i	Ì	Ì	Ì			ı	ı	ı	Į	ı	ļ	١	١	4	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	IVIVIA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	l	l	l		i		R	R	R	R	R	R	R	R	R	R	R	R	2	3	3			Ī	ī		3	R	R	R	R	R	R	R	R	R	R	R	R	R	2		Ī		i	ī		i	i	1						ı	ı	ı	l	ı	ı	ı	ı	ı																											1	1			1	1	1			ı	ı	ı	Į	ı	ļ	١	١	4	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	IVIVIA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	l	l	l		i		R	R	R	R	R	R	R	R	R	R	R	R	2	3	3			Ī	ī		3	R	R	R	R	R	R	R	R	R	R	R	R	R	2		Ī		i	ī		i	i	1						ı	ı	ı	l	ı	ı	ı	ı	ı	ĺ															ĺ	ĺ										1	1			1	1	1		ı	ı	ı	ı	Į	ı	ļ	١	١	4	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	IVIVIA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	ı	ı	ı		i	5	R	R	R	R	R	R	R	R	R	R	R	R	2	3	3	5	5			5	3	R	R	R	R	R	R	R	R	R	₹	R	R	R	2	5			i			i	i	Ì						ı	ı	ı	l	ı	ı	ı	ı	ı	ĺ															ĺ	ĺ										Ì	Ì			Ì	Ì	Ì		ı	ı	ı	ı	Į		ļ	١	١	Δ\	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	MMA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA
Δ١	l	l	l		i		R	R	R	R	R	R	R	R	R	R	R	R	2	3	3			Ī	ī		3	R	R	R	R	R	R	R	R	R	R	R	R	R	2		Ī		i	ī		i	i	1						ı	ı	ı	l	ı	ı	ı	ı	ı																											1	1			1	1	1			ı	ı	ı	Į	ı	ļ	١	١	4	Д	Α	ΙΑ	IΑ	ИΑ	MΑ	MA	IMA	ИΜА	MMA	IVIVIA	IMMA	JMMA	JMMA	UMMA	UMMA	SUMMA	SUMMA	SUMMA	SUMMA	SUMMA	ISUMMA	N SUMMA	N SUMMA	N SUMMA	DN SUMMA	ON SUMMA	ON SUMMA	ON SUMMA

Book Value (as of June 30, 2024)	\$1.0B	Book Value (at signing)	\$2.2B
Sale Price	\$1.5B	Sale Price	\$1.9B
Est. Gain (to be recognized at closing)	\$0.5B pretax	Loss (recognized at signing)	(\$279M) pretax
Balance Sheet Presentation ¹	\$1.0B Held-for-Sale	Balance Sheet Presentation ¹	\$1.9B Held-for-Sale
Income Statement Presentation ¹	Discontinued Ops	Income Statement Presentation ¹	Continuing Operations
	Equity Earnings / (Losses)		Interest Income Through June 6, 2024

1 As of June 30, 2024 EMERSON | 12

Reconciliation of Non-GAAP Measures Underlying Growth

		2024
Underlying Sales Growth	2024 Q3	Guidance
Reported (GAAP)	11%	~15%
(Favorable) / Unfavorable FX	1%	~0.5 pts
(Acquisitions) / Divestitures	(9%)	~(9.5) pts
Underlying (non-GAAP)	3%	~6%

2024 Q3 Underlying Sales Change	Reported (GAAP)	(Favorable) / Unfavorable FX	(Acquisitions) / Divestitures	Underlying (Non-GAAP)
Intelligent Devices	1%	1%	-%	2%
Software and Control	42%	1%	(36%)	7%
Emerson	11%	1%	(9%)	3%

Reconciliation of Non-GAAP Measures Adjusted Segment EBITA

Adjusted Segment EBITA	2023 Q3	2024 Q3
Net sales	\$3,946	\$4,380
Pretax earnings (GAAP)	822	455
Pretax earnings margin (GAAP)	20.8%	10.4%
Corporate items and interest expense, net	57	367
Amortization of intangibles	169	313
Restructuring and related costs	12	54
Adjusted segment EBITA (non-GAAP)	\$1,060	\$1,189
Adjusted segment EBITA margin (non-GAAP)	26.9%	27.1%

Operating Leverage	2024 Q3	2024 Guidance
Pretax margin leverage (GAAP) Corporate items and interest expense, net / amortization of intangibles / restructuring and related costs / Test & Measurement	(85%) 152%	Low (30s) to High (20s) High 70s
Adjusted segment EBITA leverage, excluding Test & Measurement (non-GAAP)	67%	Mid to High 40s

Reconciliation of Non-GAAP Measures Adjusted Earnings

This information reconciles non-GAAP measures with the most directly comparable GAAP measure (dollars in millions, except per share amounts)

	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY2023	2024 Q1	2024 Q2	2024 Q3
Net Earnings to Common Stockholders	\$2,331	\$792	\$9,352	\$744	\$13,219	\$142	\$501	\$329
Discontinued Operations Earnings:								
Discontinued operations previously reported	(2,002)	(262)	(8,760)	(43)	(11,067)			
Copeland equity loss / (gain) – now in disc. ops			51	83	134	27	46	15
Continuing Operations Earnings	\$329	\$530	\$643	\$784	\$2,286	\$169	\$547	\$344
Amortization of intangibles	87	88	88	93	356	208	209	199
Restructuring and related	11	20	10	37	78	69	28	46
Acquisition / divestiture fees and related costs		7	36	33	77	96	16	15
Amortization of acquisition related inventory step up						217		
Discrete taxes						(57)		
Divestiture loss / (gain)				(122)	(122)		(19)	
NI investment gain		(27)	(9)	(7)	(43)			
Interest income on undeployed proceeds			(27)	(81)	(108)			
AspenTech Micromine purchase price hedge	(15)	6	(1)		(11)			
Russia business exit	47				47			
Loss on Copeland note receivable								217
Adjusted Continuing Operations Earnings	\$459	\$624	\$740	\$737	\$2,560	\$702	\$781	\$821

Restatement of Copeland equity losses are unaudited EMERSON | 15

Reconciliation of Non-GAAP Measures Adjusted EPS

This information reconciles non-GAAP measures with the most directly comparable GAAP measure (dollars in millions, except per share amounts)

									2024
	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY2023	2024 Q1	2024 Q2	2024 Q3	Guidance
Net Earnings to Common Stockholders	\$3.97	\$1.38	\$16.28	\$1.29	\$22.88	\$0.25	\$0.87	\$0.57	\$3.37 - \$3.47
Discontinued Operations Earnings:									
Discontinued operations previously reported	(3.41)	(0.46)	(15.25)	(0.07)	(19.16)				
Copeland equity loss / (gain) ¹ – now in disc. ops			0.09	0.14	0.24	0.04	0.08	0.03	(0.55 - 0.60)
Continuing Operations Earnings	\$0.56	\$0.92	\$1.12	\$1.36	\$3.96	\$0.29	\$0.95	\$0.60	\$2.82 - \$2.87
Amortization of intangibles	0.15	0.16	0.15	0.16	0.62	0.36	0.36	0.35	~1.42
Restructuring and related	0.02	0.04	0.02	0.07	0.14	0.12	0.05	0.08	~0.34
Acquisition / divestiture fees and related costs		0.01	0.07	0.06	0.13	0.17	0.03	0.02	~0.24
Amortization of acquisition related inventory step up						0.38			0.38
Discrete taxes						(0.10)			(0.10)
Divestiture loss / (gain)				(0.21)	(0.21)		(0.03)		(0.03)
NI investment gain		(0.05)	(0.02)	(0.01)	(0.07)				
Interest income on undeployed proceeds			(0.05)	(0.14)	(0.19)				
AspenTech Micromine purchase price hedge	(0.03)	0.01			(0.02)				
Russia business exit	0.08				0.08				
Loss on Copeland note receivable								0.38	0.38
Adjusted Continuing Operations Earnings	\$0.78	\$1.09	\$1.29	\$1.29	\$4.44	\$1.22	\$1.36	\$1.43	\$5.45 - \$5.50

2024

¹ The earnings from discontinued operations for 2024 are expected to be \$0.55 to \$0.60 per share, including the after-tax gain on the equity stake in Copeland.

Reconciliation of Non-GAAP Measures Free Cash Flow

				_	\$ III DIIIIOIIS
	2023 Q3	2024 Q3	9 Months Ended June 30, 2023	9 Months Ended June 30, 2024	2024 Guidance
Operating cash flow (GAAP)	\$842	\$1,067	\$1,719	\$2,244	~\$3.2
Capital expenditures	(73)	(92)	(194)	(251)	~(0.4)
Free cash flow (non-GAAP)	\$769	\$975	\$1,525	\$1,993	~\$2.8

Reconciliation of Non-GAAP Measures Test & Measurement (T&M)

		2024
Earnings Per Share	2024 Q3	Guidance
Earnings per share - T&M contribution (GAAP)	(\$0.15)	(\$0.98) - (\$0.96)
Amortization of intangibles	0.18	~0.75
Restructuring and related costs	0.05	~0.20
Amortization of acquisition-related inventory step-up	-	0.36
Acquisition-related costs	0.01	~0.09
Adjusted earnings per share - T&M contribution (non-GAAP)	\$0.09	\$0.42 - \$0.44

Test & Measurement Adjusted Segment EBITA Margin	2024 Q3
T&M segment margin (GAAP)	(24.7%)
Amortization of intangibles & restructuring and related costs	46.1%
T&M adjusted segment EBITA margin (non-GAAP)	21.4%

Reconciliation of Non-GAAP Measures AspenTech

Earnings Per Share	2024 Q3	2024 Guidance
Earnings per share (GAAP)	\$0.05	(\$0.06) - (\$0.04)
Amortization of intangibles	0.09	~0.37
Restructuring and related costs	-	~0.01
Adjusted earnings per share (non-GAAP)	\$0.14	\$0.32 - \$0.34

Reconciliation of Non-GAAP Measures Other

	June 30, 2024
Backlog (GAAP)	\$8.7
AspenTech	(1.3)
Backlog excluding AspenTech (non-GAAP)	\$7.4

Endnotes

Continuing Operations

With the June 6, 2024 definitive agreement to completely exit its remaining interests in the Copeland joint venture, Emerson will report financial results for the Copeland equity ownership as discontinued operations for all periods presented, beginning in Q3 2024. The earnings from discontinued operations for 2024 are expected to be \$0.55 to \$0.60 per share, including the after-tax gain on the equity stake in Copeland. The Company's 2024 continuing operations after the complete Copeland divestiture (assumed to close by the end of August 2024) will include interest income earned from the Copeland Note Receivable through June 6, 2024. The pretax loss on the sale of the note receivable, \$279M (\$217M after-tax), is also reported in continuing operations but excluded from adjusted earnings per share, (\$0.38).